| Otarmeni by Regeneron | RP Regeneron Pharmaceuticals | Therapeutic | - | Gene Therapy | Approved | Approved | Details checkedStrong evidence | regulatory · Priority 1 | 99% | PediatricAdult+6 | Hearing LossSensorineural Hearing Loss+3 | |
| PEDMARK by Fennec Pharmaceuticals | FP Fennec Pharmaceuticals | Therapeutic | - | Small Molecule | Marketed | Marketed | Details checkedStrong evidence | regulatory · Priority 1 | 98% | PediatricCisplatin Ototoxicity | Cisplatin-Induced Hearing LossHearing Loss | |
| AK-OTOF by Eli Lilly and Akouos | EL Eli Lilly and Company | Therapeutic | - | Gene Therapy | Phase 2 | Active | Details checkedStrong evidence | trial · Priority 1 | 95% | PediatricAdult+6 | Hearing LossSensorineural Hearing Loss+3 | |
| SENS-401 (Arazasetron) by Sensorion | S Sensorion | Therapeutic | - | Small Molecule | Phase 2 | Active | Details checkedStrong evidence | company · Priority 1 | 94% | AdultSudden / SSNHL+2 | Hearing LossSensorineural Hearing Loss+2 | |
| SENS-501 by Sensorion | SSensorion | Therapeutic | - | Gene Therapy | Phase 1/2 | Active | Details checkedStrong evidence | trial · Priority 1 | 94% | PediatricCongenital+5 | Hearing LossSensorineural Hearing Loss+3 | |
| Envoy Medical Acclaim Cochlear Implant | | Device | Cochlear Implants | Cochlear/Auditory Implant | Phase 2/3 | Active | Details checkedStrong evidence | trial · Priority 1 | 93% | AdultPost-Lingual+1 | Hearing LossSensorineural Hearing Loss | |
| SPI-1005 by Sound Pharmaceuticals | SP Sound Pharmaceuticals | Therapeutic | - | Small Molecule | Phase 3 | Active | Details checkedStrong evidence | trial · Priority 1 | 90% | AdultNoise-Induced+2 | Hearing LossSensorineural Hearing Loss+3 | |
| ACOU085 by Acousia Therapeutics | AT Acousia Therapeutics GmbH | Therapeutic | - | Small Molecule | Phase 2 | Active | Details checkedStrong evidence | company · Priority 2 | 93% | AdultAge-Related+1 | Hearing LossSensorineural Hearing Loss+2 | |
| Natus AURICAL FreeFit | | Diagnostic | Diagnostics | Diagnostic/Fitting Verification | Marketed | Marketed | Details checkedStrong evidence | company · Priority 2 | 90% | AdultPediatric+3 | Hearing LossSensorineural Hearing Loss | |
| Tympa Platform Ear and Hearing Health System | | Diagnostic | Diagnostics | Diagnostic | Marketed | Marketed | Details checkedStrong evidence | company · Priority 2 | 90% | AdultPediatric+1 | Hearing LossCerumen Impaction+1 | |
| Paradromics Connexus BCI | | Software/Neurotech | Auditory BCI / Neurotech | BCI/Neurotech | Interventional/NA | Active | Details checkedStrong evidence | company · Priority 2 | 89% | AdultImplantable Bci+4 | Communication ImpairmentSevere Paralysis+2 | |
| ONWARD ARC-BCI / DigitalBridge | | Software/Neurotech | Auditory BCI / Neurotech | BCI/Neurotech | Interventional/NA | Active | Details checkedStrong evidence | publication · Priority 2 | 88% | AdultImplantable Bci+4 | Severe ParalysisCommunication Impairment | |
| Neurotone LACE Pro Auditory Training | | Procedure/Rehab | Rehab & Procedures | Auditory Rehabilitation Software | Marketed | Marketed | Details checkedStrong evidence | company · Priority 2 | 86% | AdultAuditory Training+4 | Hearing LossCommunication Impairment+1 | |
| OTO-313 by Otonomy | O Otonomy | Therapeutic | - | Small Molecule | Phase 2 | Discontinued | Details checkedStatus confirmedHistorical/discontinued | company · Priority 2 | 96% | AdultTinnitus+1 | Tinnitus | |
| OTO-413 by Otonomy | OOtonomy | Therapeutic | - | Biologic | Phase 2 | Discontinued | Details checkedStatus confirmedHistorical/discontinued | company · Priority 2 | 95% | AdultNoise-Induced | Hearing LossSensorineural Hearing Loss+2 | |
| DB-020 by Regeneron and Decibel | RPRegeneron Pharmaceuticals | Therapeutic | - | Drug Delivery | Phase 1 | Completed | Details checkedStatus confirmedHistorical/discontinued | publication · Priority 2 | 92% | AdultCisplatin Ototoxicity | Cisplatin-Induced Hearing LossHearing Loss | |
| NHPN-1010 | OP Otologic Pharmaceutics | Therapeutic | - | Small Molecule | Phase 1 | Completed | Details checkedStatus confirmedHistorical/discontinued | company · Priority 2 | 89% | AdultNoise-Induced+1 | Hearing LossSensorineural Hearing Loss+2 | |
| OTO-825 by Otonomy | OOtonomy | Therapeutic | - | Gene Therapy | Preclinical | Discontinued | Details checkedStatus confirmedHistorical/discontinued | company · Priority 2 | 87% | PediatricCongenital+2 | Hearing LossSensorineural Hearing Loss+1 | |
| Synchron Stentrode / SWITCH BCI | | Software/Neurotech | Auditory BCI / Neurotech | BCI/Neurotech | Interventional/NA | Active | Details checkedClinical trial listing only | registry+publication+company · Priority 2 | 92% | AdultImplantable Bci+4 | Communication ImpairmentSevere Paralysis+2 | |
| EHT102 by EuHearing | SE Shanghai EuHearing Therapeutics Co., Ltd | Therapeutic | - | Gene Therapy | Phase 1/2 | Active | Details checkedClinical trial listing only | trial · Priority 2 | 90% | PediatricGenetic+3 | Hearing LossSensorineural Hearing Loss+3 | |
| OTOV101N + OTOV101C by OtoVia Therapeutics | OT OtoVia Therapeutics | Therapeutic | - | Gene Therapy | Interventional/NA | Unknown | Details checkedClinical trial listing only | registry+publication · Priority 2 | 86% | PediatricAdult+3 | Hearing LossSensorineural Hearing Loss+2 | |